Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 10/20 | 0.48 |
| ▸ | NMT2 | O60551 | 9/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.46 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.46 |
| ▸ | NPY1R | P25929 | 2/20 | 0.41 |
| ▸ | NPY2R | P49146 | 2/20 | 0.41 |
| ▸ | NPY4R | P50391 | 2/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.41 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18909077 | 0.91 | NMT1 (0.48) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL17722904 | 0.91 | NMT1 (0.45) | NMT1NMT2TLR2NPY1RNPY2R | |
| SCHEMBL23436462 | 0.90 | NMT1 (0.46) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL20889000 | 0.90 | NMT1 (0.46) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL17722910 | 0.89 | PTGS1 (0.46) | NMT1NMT2TLR2ROCK2NPY1R | |
| SCHEMBL18932741 | 0.89 | PTGS1 (0.46) | NMT1NMT2TLR2ROCK2NPY1R | |
| SCHEMBL18937746 | 0.88 | NPY5R (0.40) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL17722903 | 0.88 | NPY5R (0.40) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL19257624 | 0.88 | NPY5R (0.38) | NMT1NMT2TLR2ROCK2PRKACA | |
| SCHEMBL13078356 | 0.88 | NPY5R (0.38) | NMT1NMT2TLR2ROCK2PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-4233909-A2 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3804765-A1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Biotherapeutics Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2020236797-A1 | VARIANT CD58 DOMAINS AND USES THEREOF | NOVARTIS AG (CH) | 2020-11-26 | — | — | WO | disclosed |
| EP-3212668-B1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3458102-B1 | ANTI-CMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3383909-B1 | ANTI-HUMAN LRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2017-12-07 | — | — | US | disclosed |
| WO-2017201204-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE BIOTHERAPEUTICS INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017095805-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017095808-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
| US-20160122430-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | NMT1 1208/4885NMT2 1110/4885TLR2 2881/4885 |
| US-20170151344-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | NMT1 1208/4885NMT2 1110/4885TLR2 2881/4885 |
| US-20160122430-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD47, CSGALNACT1, CSE1L | NMT1 1104/4885NMT2 1659/4885TLR2 4752/4885 |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | NMT1 92/4885NMT2 82/4885TLR2 3933/4885 |
| US-20230321271-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | NMT1 92/4885NMT2 82/4885TLR2 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.